P-glycoprotein, encoded by the ABCB1 gene, confers multi-drug resistance to a variety of antineoplastic agents, e.g. paclitaxel. Recently, the G1199T/A polymorphism in the ABCB1 gene was shown to be important for the function of P-glycoprotein as well as for the resistance to several chemotherapeutic agents in vitro. We analyzed the allelic distribution of the G1199T/A and other polymorphisms in exons 11 and 12 of the ABCB1 gene in ovarian cancer patients treated with paclitaxel and carboplatin in order to evaluate their predictive value in vivo. The SNPs C1236T, G1199T/A and A1308G were determined using Pyrosequencing in 51 patients with advanced ovarian cancer and correlated to the progression free survival. The G1199T/A SNP was found to affect the progression free survival. Although only two heterozygous (G/A) patients were found their mean progression free survival was only 2 months as compared to 19 months for the wild-type patients. This is in accordance with the higher resistance for the 1199A genetic variant found in vitro. Genotyping of the ABCB1 gene may be important for determining the tumor resistance to paclitaxel and provide useful information for individualized therapy.
Introduction
Crouthamel et al. 1 reported that the single nucleotide polymorphism (SNP) G1199T/A in ABCB1 is important for the in vitro resistance to several chemotherapeutic agents including paclitaxel. The transport activity of P-glycoprotein (P-gp), encoded by the ABCB1 gene, affects the pharmacokinetics of paclitaxel in several ways. Overexpression of P-gp on tumor cells resulting in an enhanced efflux of the drug is a known in vitro resistance mechanism for paclitaxel 2, 3 . Clinical resistance and poor response have also been correlated with a high expression of P-gp in tumours [4] [5] [6] . Studies in knock-out mice and co-administrations of P-gp inhibitors have shown that P-gp limits the oral uptake of paclitaxel and mediates the direct excretion of the drug from the systemic circulation as well as the absorption (or re-absorption)
of paclitaxel in the intestine [7] [8] [9] . The penetration of paclitaxel to the cerebrospinal fluid has also been shown to be dependent on the P-gp 10, 11 .
Recently we showed that the SNP G2677T/A correlated with the response to paclitaxel treatment in ovarian cancer 12 , although other studies have given different results 13, 14 . The importance of P-gp transport for the effects of paclitaxel treatment, our previous findings and the shown impact of the G1199T/A SNP on the in vitro resistance led us to investigate the clinical importance of this SNP during paclitaxel treatment of ovarian cancer.
Material and Methods
To evaluate the relationship between the response to paclitaxel treatment and the G1199T/A and others SNPs in exon 11 and 12 of the ABCB1 gene (G1199T/A, C1236T and A1308G),
we retrospectively identified the SNPs in 51 epithelial ovarian tumors (FIGO stage IIB-IV) included in a previous study 12 . All three SNPs were investigated due to their close proximity to each other. After primary surgery all patients had been treated with paclitaxel at a dose of 175 mg/m 2 or 135 mg/m 2 (n=5) in combination with carboplatin for at least four cycles. The patient and tumor characteristics are presented in the table.
Eleven tumours were collected from paraffin embedded tissues stored at the Division of Molecular and Immunological Pathology, Linköping University, and 40 tumors were freshfrozen and obtained from a bio-bank at the Department of Oncology, Sahlgrenska Academy at Göteborg University. This study was approved by the regional ethics committees in Linköping, Sweden.
DNA Isolation, PCR and Pyrosequencing
Genomic DNA was isolated using QIAamp All primers were obtained from Invitrogen (Paisley, U.K).
Statistical Analysis
The statistical analysis was performed with the SPSS software package version 14.0 (SPSS Inc. Chicago, IL, USA). Kaplan-Meier plots were used to visualize and study differences in fractions of patients with progression-free survival (PFS) between different genotypes.
Results
The PCR amplification of exon 11 and exon 12 of the ABCB1 gene resulted in single improved with increasing number of variant alleles 12 . Two groups later published results from similar studies, but with different outcome 13, 14 . However, the differences might be explained by variations in the composition and/or subdivision of tumor material and/or patients 16 . In vitro a slightly higher efflux of bodipy-FL-paclitaxel has also been shown in HeLa cells expressing the wild type P-gp than cells carrying a plasmid containing the 2677T variant 17 . In this system no effect of the G1199A genetic variant was seen on the efflux of paclitaxel.
However, the fluorescent bodipy modification of the P-gp substrates and the usage of only one substrate concentration may have influenced the ability to distinguish differences between the genetic variants of the ABCB1 gene.
In conclusion, this study indicates that the SNP G1199T/A in ABCB1 influences the response to paclitaxel-carboplatin treatment in ovarian cancer. However, the potential importance of the ABCB1 genotype as a predictive marker for paclitaxel treatment is still elusive and future studies will hopefully clarify the significance of these SNPs.
